Table 1.

Renal and clinical features in 16 patients with PAPSa

Patient Age (yr) Gender Creatinine (mg/dl) Proteinuria (g/d) Hematuria BP (mmHg) Platelets/mm3 LA aCL (UGPL) Thrombosis/Abortions Other Clinical Features
124M1.23--180/110100,000+5Pulmonary, cerebralCNS manifestations (stroke), livedo reticularis, leg ulcers, pulmonary HT
233M1.590.4+160/9585,000+>860DVTLeg ulcers, cardiac valve lesions, alveolar hemorrhage
334M1.363-260/120110,000+60Cerebral, DVTCNS manifestations (stroke), livedo reticularis
436M2.52+140/95130,000+600CerebralCNS manifestations (seizures, chorea, stroke), cardiac valve lesions, alveolar hemorrhage
538M2.272+250/140100,000+17Hemodialysis vascular access, renal graft arteryMicroangiopathic hemolytic anemia
647M1.591.5-160/10080,000+280Cerebral, DVTCNS manifestations (stroke), livedo reticularis, cardiac valve lesions, alveolar hemorrhage, pulmonary HT, immune hemolytic anemia
749M1.70.5+210/120179,000+>45CerebralCNS manifestations (multi-infarcts)
850M2.043-150/9595,000+100Suprarenal aorta, mesenteric, axillary, renal arteries, pulmonary and DVTCNS manifestations (seizures), livedo reticularis, adrenal failure
952M1.590.2-150/100159,000+20Cerebral, DVTCNS manifestations (multi-infarcts)
1060M1.3--150/100176,000+9CerebralCNS manifestations (stroke), cardiac valve lesions
1124F1.170.46+160/120147,000+20DVTCNS manifestations (chorea), cardiac valve lesions
1228F1.360.4-132/84180,000+42Cerebral, DVT, abortionsCNS manifestations (multi-infarcts), livedo, preeclampsia
1332F1.02-+170/120107,000+>45AbortionsLivedo reticularis, preeclampsia, cardiac valve lesions
1435F2.57+180/110100,000+46Cerebral, abortionsCNS manifestations (multi-infarcts), livedo reticularis, cardiac valve lesions, immune hemolytic anemia
1545F1.70.6+140/95100,000+10CerebralCNS manifestations (multi-infarcts)
16 59 F 1.36 - + 190/100 168,000 + 160 Cerebral, renal artery CNS manifestations (seizures, multi-infarcts), immune hemolytic anemia
  • a PAPS, primary antiphospholipid syndrome; LA, lupus anticoagulant; aCL, anticardiolipin antibodies; UGPL, IgG phospholipid units; CNS, central nervous system; DVT, deep venous thrombosis; HT, hypertension.